Volume 28, Supplement—December 2022
SUPPLEMENT ISSUE
Surveillance
Contribution of PEPFAR-Supported HIV and TB Molecular Diagnostic Networks to COVID-19 Testing Preparedness in 16 Countries
, Katrina Sleeman, Patricia Hall-Eidson, Clement Zeh, Ravikiran Bhairavabhotla, Guoqing Zhang, Amitabh Adhikari, George Alemnji, Yolanda Rebello Cardo, Ana Pinheiro, Barbara Pocongo, Laura T. Eno, Judith D. Shang, Clement B. Ndongmo, Hilda Rosario, Orquidea Moreno, Lucia Aurora De La Cruz De León, Peter Fonjungo, Constantin Kabwe, Steve Ahuke-Mundeke, Dan Gama, Sindisiwe Dlamini, Gugu Maphalala, Tefsay Abreha, Anne Purfield, Yared Tedla Gebrehiwot, Daniel Melese Desalegn, Frank Basiye, Jane Mwangi, Nancy Bowen, Yohannes Mengistu, Shirley Lecher, Elizabeth Kampira, Muluken Kaba, Joseph Bitilinyu-Bangoh, Gillian Masamha, Sofia Omar Viegas, R. Suzanne Beard, Gerhard van Rooyen, Andreas N. Shiningavamwe, McPaul I.J, Nnaemeka C. Iriemenam, Nwando Mba, Catherine Okoi, Joel Katoro, Dennis L Kenyi, Bior K. Bior, Christina Mwangi, Susan Nabadda, Pontiano Kaleebu, Samuel L. Yingst, Prisca Chikwanda, Levi Veri, Raivi Simbi, and Heather Alexander
Table 4
PEPFAR-supported decentralized laboratories and instruments used for SARS-CoV-2 testing in 16 countries in their response to the COVID-19 pandemic, April 1, 2020–March 31, 2021*
| Country | No. PEPFAR sites | No. (%) PEPFAR sites conducting SARS-CoV-2 testing | No. TB tests conducted in PEPFAR sites† | No. HIV VL and EID tests conducted in PEPFAR sites† | No. SARS-CoV-2 tests conducted in PEPFAR sites | No. SARS-CoV-2 tests conducted nationally | % SARS-CoV-2 tests performed at PEPFAR sites‡ |
|---|---|---|---|---|---|---|---|
| Angola | 4 | 0 (0) | NA | NA | No data | NA | NA |
| Cameroon | 13 | 0 (0) | NA | NA | No data | NA | NA |
| DR | 11 | 7 (64) | 18,519 | 3,133 | 1,240 | 1,176,196§ | 0.1 |
| DRC | 18 | 2 (11) | NA | NA | No data | No data | NA |
| Eswatini | 32 | 1 (3) | 18,243 | 1,196 | 873 | No data | NA |
| Ethiopia | 280 | 0 (0) | NA | NA | No data | NA | NA |
| Kenya | 158 | 0 (0) | NA | NA | No data | NA | NA |
| Lesotho | 33 | 3 (9) | 19,596 | 15,046 | 21,946 | No data | NA |
| Malawi | 89 | 35 (39) | 33,450 | 43,602 | 10,482 | 56,987¶ | 18.4 |
| Mozambique | 161 | 6 (4) | 159,685 | 0 | 10,332 | 472,224# | 2.2 |
| Namibia | 45 | 4 (9) | NA | NA | No data | NA | NA |
| Nigeria | 400 | 27 (7) | 56,183 | 0 | 39,902 | 702,055§ | 5.7 |
| South Sudan | 17 | 17 (100) | 4,024** | 1,081** | 2,931** | 41,171¶ | 7.1 |
| Uganda | 250 | 0 (0) | NA | NA | No data | NA | NA |
| Zambia | 300 | 3 (1) | 150,000 | 6,000 | 27,000 | 1,218,207¶ | 2.2 |
| Zimbabwe |
122 |
33 (27) |
8,326 |
1,247 |
9,976 |
428,121# |
2.3 |
| Total | 1,933 | 138 (7.1) | 468,026 | 71,305 | 124,682 | 4,094,961 | 2.5 |
*DR, Dominican Republic; DRC, Democratic Republic of Congo; EID, early infant diagnosis; NA, not applicable; PEPFAR, US President’s Emergency Plan for AIDS Relief; VL, viral load. †Number of HIV VL and EID and national SARS-CoV-2 tests are only shown for those countries reporting SARS-CoV-2 testing volumes in PEPFAR-supported laboratories. For countries not reporting SARS-CoV-2 testing volumes in PEPFAR-supported laboratories, HIV VL and EID and national SARS-CoV-2 test numbers are listed as NA. ‡Percentage of SARS-CoV-2 tests performed at PEPFAR-supported laboratories was only calculated for countries with data available for both PEPFAR and national SARS-CoV-2 testing numbers. For countries without both PEPFAR and national SARS-CoV-2 testing numbers available, % of SARS-CoV-2 tests performed at PEPFAR laboratories is listed as NA. §National SARS-CoV-2 test numbers represent the number of PCR tests. ¶Test type for national SARS-CoV-2 test numbers was uncited or listed as unclear. #National SARS-CoV-2 test numbers represent the number of PCR and antigen tests. **Testing numbers reported in South Sudan PEPFAR laboratories represent the period October 2020–March 2021.